Wan-Guang Zhang

Quick facts

Marketed products

• Nocardia rubra cell wall skeleton

Phase 2 pipeline

• Camrelizumab plus Apatinib · Oncology
  Camrelizumab is a PD-1 inhibitor, and Apatinib is a VEGFR-2 tyrosine kinase inhibitor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Wan-Guang Zhang portfolio CI brief
• Wan-Guang Zhang pipeline updates RSS